Becton, Dickinson Responds to FDA Alerts by Increasing Syringe Manufacturing Locally
Thursday, 21 March 2024, 14:22
Becton, Dickinson Boosts Syringe Production
Following recent FDA concerns over plastic syringe quality issues from China, Becton, Dickinson (BDX) has decided to scale up its domestic manufacturing of syringes.
Key Points:
- Local Production: Becton, Dickinson is increasing syringe production in the U.S. to address quality control concerns.
- Strategic Decision: Responding to FDA alerts, the company aims to ensure compliance with regulatory standards.
- Supply Chain Reliability: The move seeks to secure a dependable supply chain amidst regulatory challenges.
The decision to expand local production emphasizes BD's commitment to quality and regulatory standards, safeguarding the safety and efficacy of its syringe offerings.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.